Translate this page into:
Intense Fluorodeoxyglucose Uptake in Aggressive Systemic Mastocytosis without Associated Hematological Neoplasm: Unusual Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Presentation
Address for correspondence: Prof. Maseeh U. Z. Zaman, Department of Radiology, Aga Khan University Hospital, Karachi, Pakistan. E-mail: maseeh.uzzaman@aku.edu
-
Received: ,
Accepted: ,
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
This article was originally published by Wolters Kluwer - Medknow and was migrated to Scientific Scholar after the change of Publisher.
Abstract
Systemic mastocytosis (SM) is a relatively rare heterogeneous group of disorders characterized by uncontrolled proliferation and accumulation of clonal mast cells in one or more organs. Indolent SM is the most common variety. Less common variety is aggressive systemic mastocytosis (aSM) type with or without associated hematological neopalsm (AHN). Fludeoxyglucose (FDG) positron emission tomography/computed tomography has a limited role in aSM without AHN as these exhibit low FDG avidity. We are presenting a biopsy-proven case of aSM without AHN showing abnormally high FDG uptake in lesions involving skin, nodes, marrow, and muscles.
Keywords
Aggressive systemic mastocytosis with associated hematological neopalsm
Aggressive systemic mastocytosis without associated hematological neopalsm
fludeoxyglucose positron emission tomography/computed tomography presentation
systemic mastocytosis
Introduction
Mastocytosis is a heterogeneous group of disorders characterized by uncontrolled proliferation and accumulation of clonal mast cells in one or more organs.[1] Molecular hallmark is c-kit D816V mutation, and in <20% of cases, either a different mutation or no mutation has been reported.[2] The most common presentation is a cutaneous lesion (urticarial pigmentosa) without organ dysfunction and anaphylaxis caused by the release of mast cell mediators (80% – Indolent systemic mastocytosis [ISM]). In 15% of cases, it follows an advanced course such as aggressive SM (aSM), SM with associated hematological neoplasm (AHN), MC leukemia, or sarcoma with dysfunction of one or more organs.[2] The low prevalence and unusual features of SM often hinder its diagnosis for several years.[3] Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) imaging is considered not a sensitive tool for mast cell activation and proliferation which cannot distinguish between indolent and purely aSM.[2]
We are presenting a case of a young man with biopsy-proven aSM without AHN disease showing abnormally high metabolic activity on FDG PET/CT imaging which is atypical and unusual for the condition.
Case Report
A 37-year-old male presented with a 3-month history of maculopapular cutaneous lesions (urticaria pigmentosa) over the neck and both upper arms, recurrent low-grade fever, and episodes of bronchospasms. Contrast-enhanced computerized tomography performed revealed lymphadenopathy in the bilateral neck and mediastinum, with splenomegaly and areas of skin thickenings in the neck and both upper arms. His skin biopsy (December 28, 2021) revealed mastocytosis, and bone trephine from the sternum (January 12, 2022) revealed bone marrow involvement by mastocytosis with normal erythroid and myeloid precursors. Histopathological diagnosis was aSM without AHN. To evaluate the extent of disease and response evaluation to therapy, an FDG PET/CT was performed. Noncontrast low-dose FDG PET/CT was performed using Celestion, Cannon (Japan).
FDG PET/CT revealed hypermetabolic enlarged lymph nodes in bilateral neck (largest in left supraclavicular (47 mm × 36 mm SUVmax 10), axillae (right 22 mm × 34 mm SUVmax 11.4), and mediastinum (largest right paratracheal 44 mm × 30 mm SUVmax 10) [Figure 1a–i]. The spleen was enlarged (170 mm CC) with diffuse FDG uptake (SUVmax 5.8). Mild diffuse marrow uptake with small focal deposits was seen to suggest marrow disease. There were also multiple hypermetabolic deposits in muscles of the neck, shoulders, and both pectoral regions and hypermetabolic skin lesions over the right anterolateral chest wall and sternal (SUVmax 10.5) regions [Figure 1a–i].
Discussion
SM is a relatively rare disease with a reported prevalence of 1 in 10,000 persons.[45] According to a multicenter French study, FDG PET/CT imaging shows no significant metabolic activity in smoldering and purely aSM without AHN but intense FDG uptake in the marrow and other sites seen in aSM with AHN.[2] In a recently published case report by Koukalová et al., a patient with aSM had diffusely low FDG uptake on lesions seen on CT but enhanced marrow uptake and marrow biopsy revealed kit D816V mutation, which is considered minor criteria for diagnosing SM.[6] In contrary to above mentioned case, our case revealed intense FDG uptake overall. Based on these published facts, FDG PET/CT is considered to have limited utility for estimating the prognosis and assessing the therapeutic effects in ISM and aSM without AHN. Interestingly, our patient with aSM without AHN revealed intense hypermetabolism. It is also important to mention that our case also exhibited significant mast cell infiltration in various muscle groups, which is an unusual finding. This case report also favors the utility of FDG PET/CT in response evaluation in such rare with positive baseline FDG PET/CT (although we do not have a posttreatment FDG PET/CT). We conclude that this case report would add to existing data showing an unusual presentation of aSM without AHN showing intense FDG uptake which is considered to have low-to-no FDG avidity. In these patients, FDG PET/CT may be used for response assessment.
Informed consent
Written informed consent was obtained from the patient for publication.
Declaration of patient consent
The authors certify that they have obtained appropriate patient consent for conducting tests and using clinical information for publication as per institutional policy. The patient understands that his name and initials will not be published and due efforts will be made to conceal his identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
References
- Case report: Mastocytosis: The long road to diagnosis. Front Immunol. 2021;12:635909.
- [Google Scholar]
- FDG-PET/CT findings in systemic mastocytosis: A French multicentre study. Eur J Nucl Med Mol Imaging. 2015;42:2013-20.
- [Google Scholar]
- The Mastocytosis Society survey on mast cell disorders: Patient experiences and perceptions. J Allergy Clin Immunol Pract. 2014;2:70-6.
- [Google Scholar]
- Epidemiology, prognosis, and risk factors in mastocytosis. Immunol Allergy Clin North Am. 2014;34:283-95.
- [Google Scholar]
- Aggressive systemic mastocytosis with diffuse bone marrow 18F-FDG uptake. Nuklearmedizin. 2022;61:58-61.
- [Google Scholar]